While it sounds like good news (and I'm not an expert on this as I've started learning about the stock market since January of this year), I would be hesitant to buy in mainly because of the ending of the article. 1) It doesn't state how much of their incoming revenue will be going toward capital vs. corporate purposes. 2) It states that there are only 12 employees, which seems pretty small for being able to actually produce anything when compared to larger pharma companies (e.g. Johnson & Johns